Findings A UCLA research team has shown that using a truncated form of the CD4 molecule as part of a gene therapy to combat HIV yielded superior and longer-lasting results in mouse models than previous similar therapies using the CD4 molecule. This new approach to CAR T gene therapy — a type of immunotherapy that
(HealthDay)—For patients with HIV-1 suppression, long-acting cabotegravir plus rilpivirine is noninferior to oral therapy with dolutegravir-abacavir-lamivudine and standard oral therapy, according to two studies published online March 4 in the New England Journal of Medicine. Chloe Orkin, M.D., from the Queen Mary University of London, and colleagues conducted a phase 3 randomized trial involving adults
The cover for issue 54 of Oncotarget features Figure 2, “Comparative proteomic profiling of the peptides/proteins identified from 293T, IL16lamp2b and mExo-Tat samples,” by Lu, et al. The HIV-1 Tat protein is a potent activator of viral transcription. The researcher’s previous work has demonstrated that exosomal formulations of Tat can reverse HIV-1 latency in primary
A mutation that causes a type of muscular dystrophy that affects the limbs protects against HIV-1 infection, according to a study published August 29 in the open-access journal PLOS Pathogens by Sara Rodríguez-Mora, Mayte Coiras and José Alcamí of the Instituto de Salud Carlos III in Madrid, Spain, and colleagues. As the authors noted, this
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok